Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media

  • Circio´s position as a pioneering player in the rapidly emerging circular RNA field is being recognized in the industry
  • Five articles and interviews have recently been published in widely read EU and US life science publications with a combined readership of over 3 million
  • Additional high-profile interviews are expected to generate further coverage in the coming months 

Oslo, Norway, 25 June 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, today announces that it has initiated a systematic strategy to raise its international profile, and increase the awareness of the therapeutic potential of circular RNA (circRNA), across key life science stakeholders, including investors, pharma partners, grant providers, regulators and key international journalists. To date, this effort has generated numerous meetings and interviews, and resulted in five recently published articles in life science industry media. These publications have a combined biopharma readership of over three million.

The five articles cover both circular RNA in general and Circio specifically:

Harnessing the Therapeutic Potential of Circular RNA

Technology Networks, 10 April 2024

Circio mulls acquiring players with drug delivery or gene therapy vector technology – CEO

MergerMarket, 1 May 2024

Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised

Clinical Trials Arena, a GlobalData publication 15 May 2024

Enhancing gene therapy with Circio

Drug Target Review, 22 May 2024

The therapeutic potential of circular RNA

Mednous, 22 May 2024

The initiative to raise Circio´s profile and circular RNA awareness was taken following the generation of in vivo proof-of-concept data demonstrating the potential of Circio´s circVec vector expression system as a powerful platform to enhance current gold-standard gene therapy. Veteran life science communication’s expert Neil Hunter is supporting Circio in these efforts through his decades of communication experience for generating interviews and coverage in key selected international life science titles to attract attention across the sector.

“Circio has an ambitious long-term development strategy to build the circVec circular RNA platform into the future gold-standard expression system for gene therapy. This could be transformative for patients with few or no therapeutic options today,” said Erik Digman Wiklund, CEO of Circio. “Over 40% of all RNA VC investment in the past four years has been placed into circular RNA and the first circRNA therapeutics are now being prepared for clinical entry. Circio has worked systematically to support our position as discoverers of, and a leader in, the rapidly expanding circRNA field. This effort is now bearing fruit through a number of articles featuring Circio in industry media that have in turn resulted in an increasing flow of incoming requests regarding our unique circVec platform. This creates important visibility and validation for our technology to support the aim of entering our first strategic partnership within the next twelve months.”

In addition to the published articles, Circio’s recent press releases have been covered broadly by industry media, including BioCentury, BioWorld, The Medicine Maker, Pharmaceutical Technology, News Medical, Drug Discovery World, Technology Networks, BioPharma Reporter, The Pharma Letter and Pharma Times. Circio management have also met with journalists from STAT News, Endpoints News and BioSpace, which have a combined readership of over 10 million life science professionals internationally.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536

Lubor Gaal, CFO
Phone: +34 683343811

Neil Hunter, Hunter PR
Phone: +44 7821 255568

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA gene therapies and immunotherapy medicines. Circio has established a unique circular RNA (circRNA) platform for genetic medicine. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed in multiple disease settings. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in three clinical trials: RAS-mutated pancreatic cancer and lung and non-resectable pancreatic cancer in US, and multiple myeloma in Norway. These studies are being run through academic collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.